Solvency ratios also known as long-term debt ratios measure a company ability to meet long-term obligations.
Paying user area
Try for free
Amgen Inc. pages available for free this week:
- Cash Flow Statement
- Common-Size Balance Sheet: Assets
- Analysis of Liquidity Ratios
- Price to FCFE (P/FCFE)
- Capital Asset Pricing Model (CAPM)
- Present Value of Free Cash Flow to Equity (FCFE)
- Selected Financial Data since 2005
- Return on Equity (ROE) since 2005
- Current Ratio since 2005
- Price to Operating Profit (P/OP) since 2005
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Amgen Inc. for $24.99.
This is a one-time payment. There is no automatic renewal.
We accept:
Solvency Ratios (Summary)
Based on: 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
The solvency position, as indicated by the presented ratios, demonstrates a generally improving trend over the observed period, though with some fluctuations. Initially, the metrics suggest a relatively leveraged capital structure, which subsequently shows signs of stabilization and modest improvement. A closer examination of individual ratios reveals nuanced patterns.
- Debt to Equity
- The debt to equity ratio experienced a significant decline from 40.23 in March 2022 to 10.60 in September 2022, indicating a substantial reduction in leverage. This trend continued, albeit at a slower pace, reaching a low of 7.57 in June 2025. A slight increase to 6.31 is observed in December 2025, but remains considerably lower than the initial value. This suggests a deliberate effort to reduce reliance on equity financing or an increase in equity.
- Debt to Capital
- The debt to capital ratio exhibits a consistent, though gradual, downward trend throughout the period. Starting at 0.98 in March 2022, it decreased to 0.86 in December 2025. This indicates a decreasing proportion of debt relative to the total capital structure, aligning with the observations from the debt to equity ratio. The changes are relatively small, suggesting a controlled and steady de-leveraging process.
- Debt to Assets
- Similar to the debt to capital ratio, the debt to assets ratio shows a consistent decline, moving from 0.62 in the first three quarters of 2022 to 0.60 in December 2025. This reinforces the observation of a decreasing reliance on debt financing and a strengthening asset base relative to liabilities.
- Financial Leverage
- Financial leverage demonstrates a more volatile pattern. It decreased substantially from 64.62 in March 2022 to 9.37 in September 2025, mirroring the decline in debt ratios. However, a slight increase to 10.46 is noted in December 2025. The initial high value suggests significant financial leverage, which has been substantially reduced over time. The recent increase warrants monitoring, but remains well below the initial levels.
- Interest Coverage
- The interest coverage ratio initially fluctuated between 6.22 and 6.97 before declining significantly to 3.73 in December 2022. It continued to decrease to a low of 2.10 in March 2024. Subsequently, the ratio began to recover, reaching 4.26 in December 2025. This suggests an initial period of comfortable interest coverage, followed by a period of increased strain, and then a gradual improvement. The recovery in the latter part of the period is a positive indicator, but the ratio remains lower than the initial values, potentially indicating increased interest expense or decreased earnings before interest and taxes.
In summary, the observed trends suggest a strategic shift towards a more conservative capital structure. While the interest coverage ratio experienced a period of decline, it has shown signs of recovery. Overall, the solvency position appears to be strengthening, although continued monitoring of the interest coverage ratio is recommended.
Debt Ratios
Coverage Ratios
Debt to Equity
| Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||||||||||||||||
| Current portion of long-term debt | |||||||||||||||||||||
| Long-term debt, excluding current portion | |||||||||||||||||||||
| Total debt | |||||||||||||||||||||
| Stockholders’ equity | |||||||||||||||||||||
| Solvency Ratio | |||||||||||||||||||||
| Debt to equity1 | |||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||
| Debt to Equity, Competitors2 | |||||||||||||||||||||
| AbbVie Inc. | |||||||||||||||||||||
| Bristol-Myers Squibb Co. | |||||||||||||||||||||
| Danaher Corp. | |||||||||||||||||||||
| Eli Lilly & Co. | |||||||||||||||||||||
| Gilead Sciences Inc. | |||||||||||||||||||||
| Johnson & Johnson | |||||||||||||||||||||
| Merck & Co. Inc. | |||||||||||||||||||||
| Pfizer Inc. | |||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | |||||||||||||||||||||
| Thermo Fisher Scientific Inc. | |||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | |||||||||||||||||||||
Based on: 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
1 Q4 2025 Calculation
Debt to equity = Total debt ÷ Stockholders’ equity
= ÷ =
2 Click competitor name to see calculations.
The debt to equity ratio exhibits considerable fluctuation over the observed period, spanning from March 31, 2022, to December 31, 2025. Initially, the ratio demonstrates a significant decline, followed by periods of relative stability and subsequent increases, culminating in a moderate level at the end of the analyzed timeframe.
- Initial Decline (Mar 31, 2022 – Sep 30, 2022)
- From March 31, 2022, to September 30, 2022, the debt to equity ratio decreased substantially, moving from 40.23 to 10.60. This reduction suggests a considerable improvement in the company’s financial leverage, potentially due to an increase in stockholders’ equity or a decrease in total debt, or a combination of both. The most significant portion of this decline occurred between March and June 2022.
- Period of Stability and Increase (Dec 31, 2022 – Dec 31, 2023)
- Following the initial decline, the ratio experienced a period of relative stability, fluctuating between 10.37 and 11.52. However, a noticeable increase is observed from September 30, 2023, to December 31, 2023, rising from 7.90 to 10.37. This increase indicates a growing reliance on debt financing relative to equity during this period.
- Fluctuations and Recent Trend (Mar 31, 2024 – Dec 31, 2025)
- The period from March 31, 2024, to December 31, 2025, is characterized by continued fluctuations. The ratio peaked at 12.75 in March 2024, then decreased to 8.02 by September 2024. A subsequent increase to 10.23 by December 2024 was followed by a decline to 5.67 in September 2025, before a final increase to 6.31 by December 31, 2025. This suggests ongoing adjustments in the capital structure. The most recent values indicate a return towards a lower, more manageable debt to equity ratio compared to the earlier periods of the analysis.
Overall, the observed trend suggests a dynamic capital structure management strategy. While the initial period demonstrated a significant deleveraging, subsequent periods show a willingness to utilize debt financing, followed by periods of reduction. The ratio’s final value indicates a moderate level of financial leverage.
Debt to Capital
| Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||||||||||||||||
| Current portion of long-term debt | |||||||||||||||||||||
| Long-term debt, excluding current portion | |||||||||||||||||||||
| Total debt | |||||||||||||||||||||
| Stockholders’ equity | |||||||||||||||||||||
| Total capital | |||||||||||||||||||||
| Solvency Ratio | |||||||||||||||||||||
| Debt to capital1 | |||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||
| Debt to Capital, Competitors2 | |||||||||||||||||||||
| AbbVie Inc. | |||||||||||||||||||||
| Bristol-Myers Squibb Co. | |||||||||||||||||||||
| Danaher Corp. | |||||||||||||||||||||
| Eli Lilly & Co. | |||||||||||||||||||||
| Gilead Sciences Inc. | |||||||||||||||||||||
| Johnson & Johnson | |||||||||||||||||||||
| Merck & Co. Inc. | |||||||||||||||||||||
| Pfizer Inc. | |||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | |||||||||||||||||||||
| Thermo Fisher Scientific Inc. | |||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | |||||||||||||||||||||
Based on: 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
1 Q4 2025 Calculation
Debt to capital = Total debt ÷ Total capital
= ÷ =
2 Click competitor name to see calculations.
The debt to capital ratio for the analyzed period demonstrates a generally stable trend with moderate fluctuations. Initially, the ratio decreased from 0.98 in March 2022 to 0.91 in September 2022, indicating a slight improvement in the company’s capital structure. A subsequent increase to 0.94 in June 2022 was followed by stabilization around 0.91 through the end of 2022. A notable increase occurred in March 2023, reaching 0.92, before decreasing to 0.89 by September 2023. The ratio experienced a slight increase to 0.91 in December 2023, followed by a decrease to 0.88 in June 2025, and a final increase to 0.86 in December 2025.
- Overall Trend
- The debt to capital ratio remained relatively consistent throughout the analyzed period, fluctuating within a narrow range of approximately 0.85 to 0.98. This suggests a consistent reliance on both debt and equity financing. The most significant shift occurred between March 2022 and September 2023, where the ratio decreased from 0.98 to 0.89.
- Recent Fluctuations
- From March 2024 to December 2025, the ratio exhibited minor oscillations. It began at 0.93, decreased to 0.88 in June 2025, and concluded at 0.86 in December 2025. These fluctuations suggest potential adjustments in the company’s financing strategies or changes in the relative values of debt and equity.
- Capital and Debt Amounts
- Total debt increased significantly from US$36.854 billion in March 2022 to US$64.613 billion in December 2022, before decreasing to US$54.604 billion in December 2025. Total capital followed a similar pattern, increasing from US$37.770 billion in March 2022 to US$70.845 billion in December 2022, and then decreasing to US$63.262 billion in December 2025. The consistent increases in both debt and capital suggest overall growth, while the subsequent decreases indicate potential debt reduction or capital return strategies.
In summary, the debt to capital ratio indicates a stable financial structure with moderate changes over the analyzed period. The company appears to maintain a consistent balance between debt and equity financing, with recent fluctuations suggesting ongoing adjustments to its capital structure.
Debt to Assets
| Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||||||||||||||||
| Current portion of long-term debt | |||||||||||||||||||||
| Long-term debt, excluding current portion | |||||||||||||||||||||
| Total debt | |||||||||||||||||||||
| Total assets | |||||||||||||||||||||
| Solvency Ratio | |||||||||||||||||||||
| Debt to assets1 | |||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||
| Debt to Assets, Competitors2 | |||||||||||||||||||||
| AbbVie Inc. | |||||||||||||||||||||
| Bristol-Myers Squibb Co. | |||||||||||||||||||||
| Danaher Corp. | |||||||||||||||||||||
| Eli Lilly & Co. | |||||||||||||||||||||
| Gilead Sciences Inc. | |||||||||||||||||||||
| Johnson & Johnson | |||||||||||||||||||||
| Merck & Co. Inc. | |||||||||||||||||||||
| Pfizer Inc. | |||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | |||||||||||||||||||||
| Thermo Fisher Scientific Inc. | |||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | |||||||||||||||||||||
Based on: 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
1 Q4 2025 Calculation
Debt to assets = Total debt ÷ Total assets
= ÷ =
2 Click competitor name to see calculations.
The debt-to-assets ratio exhibits a generally stable pattern with some notable fluctuations over the observed period. Initially, the ratio remained consistent at 0.62 for the first two quarters, then decreased slightly to 0.61 and 0.60 over the subsequent two quarters. A significant increase is then observed, rising to 0.69 in the first quarter of 2023, before stabilizing around 0.67-0.68 for the next three quarters.
- Overall Trend
- From the beginning of the period through the end of 2023, the ratio demonstrates an increasing trend, albeit with some quarterly variations. The ratio peaked at 0.69 in the first quarter of 2023. Following this peak, a gradual downward trend is apparent, decreasing to 0.60 by the end of 2025.
- Recent Performance (2024-2025)
- The ratio remained relatively stable between 0.69 and 0.66 throughout 2024. A more pronounced decrease is observed in 2025, with the ratio declining from 0.64 in the first quarter to 0.60 in the final quarter. This suggests a reduction in the proportion of assets financed by debt during this period.
- Debt and Asset Movements
- The increase in the debt-to-assets ratio in early 2023 correlates with a substantial rise in total debt, from approximately US$38.9 billion to US$61.6 billion. While total assets also increased, the debt increase was proportionally larger. Conversely, the decrease observed in 2025 coincides with a reduction in total debt, from US$57.4 billion to US$54.6 billion, while total assets remained relatively stable.
In summary, the debt-to-assets ratio indicates a period of increased leverage followed by a subsequent deleveraging trend. The fluctuations suggest active management of the company’s capital structure, with notable shifts in debt levels impacting the ratio’s overall trajectory.
Financial Leverage
| Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||||||||||||||||
| Total assets | |||||||||||||||||||||
| Stockholders’ equity | |||||||||||||||||||||
| Solvency Ratio | |||||||||||||||||||||
| Financial leverage1 | |||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||
| Financial Leverage, Competitors2 | |||||||||||||||||||||
| AbbVie Inc. | |||||||||||||||||||||
| Bristol-Myers Squibb Co. | |||||||||||||||||||||
| Danaher Corp. | |||||||||||||||||||||
| Eli Lilly & Co. | |||||||||||||||||||||
| Gilead Sciences Inc. | |||||||||||||||||||||
| Johnson & Johnson | |||||||||||||||||||||
| Merck & Co. Inc. | |||||||||||||||||||||
| Pfizer Inc. | |||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | |||||||||||||||||||||
| Thermo Fisher Scientific Inc. | |||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | |||||||||||||||||||||
Based on: 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
1 Q4 2025 Calculation
Financial leverage = Total assets ÷ Stockholders’ equity
= ÷ =
2 Click competitor name to see calculations.
The financial leverage ratio for the analyzed period demonstrates a generally decreasing trend, although with some fluctuations. Initially, the ratio exhibits a substantial decline from March 31, 2022, to June 30, 2022, followed by a continued, albeit more moderate, decrease through December 31, 2023. A subsequent increase is observed in the first half of 2024, before resuming a downward trajectory and stabilizing in the latter half of 2025.
- Initial Decline (Mar 31, 2022 – Dec 31, 2023)
- The financial leverage ratio decreased significantly from 64.62 in March 2022 to 15.59 by December 2023. This suggests a substantial reduction in the proportion of assets financed by equity during this period. The most dramatic decrease occurred between March and June 2022, potentially indicating a significant equity infusion or a reduction in debt.
- Fluctuation and Stabilization (Jan 1, 2024 – Dec 31, 2025)
- Following the decline, the ratio increased to 18.51 in March 2024, before decreasing again to 10.46 by December 2025. This fluctuation suggests a period of dynamic capital structure management. The ratio stabilizes around 10 in the latter part of the analyzed period, indicating a more consistent level of financial leverage. The decrease from the peak in March 2024 to the end of the period suggests a renewed focus on reducing reliance on debt financing.
- Relationship to Equity and Assets
- The observed trends in financial leverage are consistent with the changes in stockholders’ equity and total assets. While total assets increased substantially over the period, stockholders’ equity experienced more moderate growth, and even a decrease in some quarters. This disparity contributes to the fluctuations in the leverage ratio. The larger increase in assets relative to equity in the first half of 2023 and early 2024 likely contributed to the temporary increases in the ratio.
Overall, the company appears to have actively managed its financial leverage, initially reducing its reliance on debt and then stabilizing at a lower level. The fluctuations observed suggest a responsive capital structure strategy, potentially influenced by investment opportunities and financing conditions.
Interest Coverage
| Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||||||||||||||||
| Net income (loss) | |||||||||||||||||||||
| Add: Income tax expense | |||||||||||||||||||||
| Add: Interest expense, net | |||||||||||||||||||||
| Earnings before interest and tax (EBIT) | |||||||||||||||||||||
| Solvency Ratio | |||||||||||||||||||||
| Interest coverage1 | |||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||
| Interest Coverage, Competitors2 | |||||||||||||||||||||
| Danaher Corp. | |||||||||||||||||||||
| Gilead Sciences Inc. | |||||||||||||||||||||
| Johnson & Johnson | |||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | |||||||||||||||||||||
| Thermo Fisher Scientific Inc. | |||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | |||||||||||||||||||||
Based on: 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
1 Q4 2025 Calculation
Interest coverage
= (EBITQ4 2025
+ EBITQ3 2025
+ EBITQ2 2025
+ EBITQ1 2025)
÷ (Interest expenseQ4 2025
+ Interest expenseQ3 2025
+ Interest expenseQ2 2025
+ Interest expenseQ1 2025)
= ( + + + )
÷ ( + + + )
=
2 Click competitor name to see calculations.
The interest coverage ratio exhibits a fluctuating pattern over the observed period, spanning from March 31, 2022, to December 31, 2025. Initially, the ratio demonstrates relative stability, followed by a marked decline and subsequent recovery.
- Initial Stability and Decline (Mar 31, 2022 – Dec 31, 2023)
- From March 31, 2022, through June 30, 2022, the interest coverage ratio remained relatively consistent, fluctuating between 6.40 and 6.97. A gradual decline commenced in September 2022, continuing through December 2023, where the ratio reached a low of 3.73. This period reflects a decreasing ability to meet interest obligations from earnings before interest and tax.
- Bottoming Out and Initial Recovery (Mar 31, 2024 – Jun 30, 2024)
- The ratio reached its lowest point in December 2023. The first half of 2024 showed continued weakness, with the ratio bottoming out at 2.10 in March 2024. A modest recovery began in June 2024, with the ratio increasing to 2.45 by September 2024.
- Strengthening Trend (Sep 30, 2024 – Dec 31, 2025)
- A clear upward trend is observed from September 30, 2024, through December 31, 2025. The ratio increased from 2.45 to 4.26 over this period, indicating a strengthening capacity to cover interest expenses from earnings. The most significant improvement occurred between September 30, 2025, and December 31, 2025.
- Earnings and Interest Expense Relationship
- The decline in the interest coverage ratio between 2022 and 2023 appears to be driven by a combination of decreasing earnings before interest and tax, and increasing interest expense. While earnings fluctuated, interest expense consistently rose during this period. The subsequent recovery correlates with an increase in earnings before interest and tax, coupled with a stabilization, and eventual slight decrease, in interest expense.
Overall, the trend suggests a period of increased financial risk followed by a strengthening of the ability to service debt. The recent improvement in the interest coverage ratio is a positive indicator, but continued monitoring is warranted to assess the sustainability of this trend.